ES2061496T3 - Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante. - Google Patents

Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.

Info

Publication number
ES2061496T3
ES2061496T3 ES87304642T ES87304642T ES2061496T3 ES 2061496 T3 ES2061496 T3 ES 2061496T3 ES 87304642 T ES87304642 T ES 87304642T ES 87304642 T ES87304642 T ES 87304642T ES 2061496 T3 ES2061496 T3 ES 2061496T3
Authority
ES
Spain
Prior art keywords
cell carcinoma
basal cell
human interferon
recombinant alpha
intralesional treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87304642T
Other languages
English (en)
Inventor
Daniel Jay Tanner
Edwin Arnold Peets
Kenneth Albert Smiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2061496T3 publication Critical patent/ES2061496T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

EL CARCINOMA DE CELULAS BASALES HUMANAS SE TRATA CON EXITO MEDIANTE ADMINISTRACION INTRALESIONAL DE INTERFERON ALFA HUMANO RECOMBINANTE, ESPECIALMENTE INTERFERON ALFA-2B. SE DESCRIBE LA PREPARACION DE COMPOSICIONES FARMACEUTICAS ADECUADAS.
ES87304642T 1986-05-27 1987-05-26 Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante. Expired - Lifetime ES2061496T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86664486A 1986-05-27 1986-05-27

Publications (1)

Publication Number Publication Date
ES2061496T3 true ES2061496T3 (es) 1994-12-16

Family

ID=25348060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87304642T Expired - Lifetime ES2061496T3 (es) 1986-05-27 1987-05-26 Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.

Country Status (13)

Country Link
EP (1) EP0248583B1 (es)
JP (1) JPS62289526A (es)
KR (1) KR870010871A (es)
AT (1) ATE100717T1 (es)
AU (1) AU601741B2 (es)
CA (1) CA1295243C (es)
DE (1) DE3788899T2 (es)
DK (1) DK264787A (es)
ES (1) ES2061496T3 (es)
IE (1) IE62318B1 (es)
IL (1) IL82654A0 (es)
PH (1) PH26198A (es)
ZA (1) ZA873743B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0278715A3 (en) * 1987-02-09 1989-03-08 Schering Corporation Use of human gamma interferon for treatment of basal cell carcinoma
AU634511B2 (en) * 1988-12-01 1993-02-25 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US5256410A (en) * 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
IL100415A0 (en) * 1990-12-21 1992-09-06 Schering Corp Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
AU2018246292A1 (en) * 2017-03-31 2019-10-10 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (NMSC)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305551A3 (en) * 1981-10-13 1990-01-10 Exovir, Inc. Pharmaceutical compositions for topical application
US5098703A (en) * 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
EP0098864A1 (en) * 1982-01-15 1984-01-25 Cetus Corporation Interferon-alpha 74
AU1153083A (en) * 1982-01-15 1983-07-28 Cetus Corporation Interferon-alpha 54
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex

Also Published As

Publication number Publication date
CA1295243C (en) 1992-02-04
DK264787D0 (da) 1987-05-25
IL82654A0 (en) 1987-11-30
KR870010871A (ko) 1987-12-18
ZA873743B (en) 1987-11-25
ATE100717T1 (de) 1994-02-15
EP0248583A2 (en) 1987-12-09
IE871358L (en) 1987-11-27
JPS62289526A (ja) 1987-12-16
AU7336687A (en) 1987-12-03
DE3788899D1 (de) 1994-03-10
EP0248583B1 (en) 1994-01-26
EP0248583A3 (en) 1989-10-18
PH26198A (en) 1992-03-18
IE62318B1 (en) 1995-01-25
DE3788899T2 (de) 1994-05-05
AU601741B2 (en) 1990-09-20
DK264787A (da) 1987-11-28

Similar Documents

Publication Publication Date Title
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
MX9302160A (es) Composiciones farmaceuticas del interferon de leu cocito humano concordante.
IT1183181B (it) Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
DK0643973T3 (da) Anvendelse af humant interferon-beta til fremstilling af farmaceutiske præparater til behandling af kronisk myeloid leukæmi
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DK0382381T3 (da) Behandling af leukocyt-dysfunktion med GM-CSF
ES2115582T3 (es) Preparacion y aplicaciones de interferon-gamma.
DK328088D0 (da) Farmaceutisk komposition til behandling af tumorer
ES2058555T3 (es) Medicamento para el tratamiento intralesional del carcinoma de celulas escamosas, con alfa-interferon humano recombinante.
ES2052579T3 (es) Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.
ATE130194T1 (de) Subkutane verabreichung des humanen choriongonadotropins.
ES2039276T3 (es) Uso de una combinacion de interferon gamma e interferon alfa para la preparacion de un medicamento para el tratamiento de ciertas leucemias.
KR920014480A (ko) 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도
IT1102304B (it) Composizione farmaceutica per la cura della sordita' e del ronzio auricolare
HU900202D0 (en) Process for manufacturing of pharmaceutical compositions comprising gamma-interferon suitable to treatment of ovarion cancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 248583

Country of ref document: ES